If you liked this article you might like

AbbVie Is Still Pointed Up, for Now
S&P 500 on Track for July Gains as Alphabet, Amazon Climb
Trending Tickers: BUD, ABBV, SRCL, EXPE
Abbvie Plans to Defend Humira, Sees Upside in Oncology and Hep C Treatments